A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension

King Sum Luk, Christina Ip, Meng–Qi GONG, Sunny Hei WONG, William KK Wu, Mei DONG, Guang–Ping LI, Ka Pang Chan, Yi–Mei DU, Tong LIU, Martin CS Wong, David Shu Cheong Hui, Gary Tse, International Health Informatics Study (IHIS) Network 1 Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China 2 Li Ka Shing Institute of Health Sciences, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China 3 Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China 4 Department of Anaesthesia and Intensive Care, State Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China 5 The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Shandong University, Jinan, China 6 Research Center of Ion Channelopathy, Institute of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 7 JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China 8 State Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China

[1]  S. Wong,et al.  Cancer antigen-125 and risk of atrial fibrillation: a systematic review and meta-analysis , 2018, Heart Asia.

[2]  S. Wong,et al.  Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis. , 2018, The Journal of infection.

[3]  K. Tsuneyama,et al.  Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy. , 2017, JCI insight.

[4]  A. Mebazaa,et al.  Prognostic stratification in pulmonary hypertension: A multi-biomarker approach. , 2017, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[5]  R. Schnabel,et al.  Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction. , 2017, International journal of cardiology.

[6]  A. Maisel,et al.  Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure , 2016, Arquivos brasileiros de cardiologia.

[7]  Sanjiv J. Shah,et al.  Management of Pulmonary Arterial Hypertension , 2015, Seminars in Respiratory and Critical Care Medicine.

[8]  M. Humbert,et al.  Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. , 2014, Biochemical and biophysical research communications.

[9]  Zhi-Hong Liu,et al.  Plasma Soluble ST2 Levels Correlate With Disease Severity and Predict Clinical Worsening in Patients With Pulmonary Arterial Hypertension , 2014, Clinical cardiology.

[10]  R. D. de Boer,et al.  Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. , 2014, Clinical chemistry.

[11]  M. Yeager,et al.  Biomarkers for Pediatric Pulmonary Arterial Hypertension – A Call to Collaborate , 2013, Front. Pediatr..

[12]  Hiroki Sato,et al.  Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhoodpulmonary arterial hypertension. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[13]  H. Olschewski,et al.  Biomarkers in pulmonary hypertension: what do we know? , 2013, Chest.

[14]  W. Buhre,et al.  Temporal changes of soluble ST2 after cardiovascular interventions , 2013, European journal of clinical investigation.

[15]  T. Mueller,et al.  The Presage® ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2 , 2013, Expert review of molecular diagnostics.

[16]  M. Mildner,et al.  Primary sources and immunological prerequisites for sST2 secretion in humans. , 2010, Cardiovascular research.

[17]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[18]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[19]  Richard T. Lee,et al.  Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction , 2002, Circulation.

[20]  S. Tominaga,et al.  ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. , 2002, Biochemical and biophysical research communications.